摩熵化学
数据库官网
小程序
打开微信扫一扫
首页 分子通 化学资讯 化学百科 反应查询 关于我们
请输入关键词

2-(2-Aminoethoxy)-5-chlor-pyridin | 29450-00-8

中文名称
——
中文别名
——
英文名称
2-(2-Aminoethoxy)-5-chlor-pyridin
英文别名
2-(2-Aminoethoxy)-5-chloropyridine;2-(5-chloropyridin-2-yl)oxyethanamine
2-(2-Aminoethoxy)-5-chlor-pyridin化学式
CAS
29450-00-8
化学式
C7H9ClN2O
mdl
MFCD16714174
分子量
172.614
InChiKey
GJMGSRDVCHQVGB-UHFFFAOYSA-N
BEILSTEIN
——
EINECS
——
  • 物化性质
  • 计算性质
  • ADMET
  • 安全信息
  • SDS
  • 制备方法与用途
  • 上下游信息
  • 反应信息
  • 文献信息
  • 表征谱图
  • 同类化合物
  • 相关功能分类
  • 相关结构分类

物化性质

  • 沸点:
    260.0±30.0 °C(Predicted)
  • 密度:
    1.243±0.06 g/cm3(Predicted)

计算性质

  • 辛醇/水分配系数(LogP):
    0.8
  • 重原子数:
    11
  • 可旋转键数:
    3
  • 环数:
    1.0
  • sp3杂化的碳原子比例:
    0.285
  • 拓扑面积:
    48.1
  • 氢给体数:
    1
  • 氢受体数:
    3

文献信息

  • [EN] NEW-4-(PYRROLOPYRIMIDIN-6-YL)BENZENESULPHONAMIDE DERIVATIVES<br/>[FR] NOUVEAUX DERIVES DE 4-(PYRROLOPYRIMIDIN-6-YL)BENZENESULPHONAMIDE
    申请人:ALMIRALL PRODESFARMA SA
    公开号:WO2003082873A1
    公开(公告)日:2003-10-09
    This invention is directed to new potent and selective antagonists of A2A and/or A2B adenosine receptors having the general formula (I) to process for their preparation; to pharmaceutical compositions comprising them; and to their use in therapy.
    这项发明是针对新型高效选择性A2A和/或A2B腺苷受体拮抗剂的,其具有通用公式(I),用于其制备的过程;包含它们的药物组合物;以及它们在治疗中的应用。
  • COMPOUNDS FOR TREATING DISORDERS SENSITIVE TO SEROTONINERGIC REGULATION CONTROLLED BY THE 5-HT1A RECEPTORS
    申请人:Neurolixis
    公开号:EP3260452A1
    公开(公告)日:2017-12-27
    The invention concerns compounds that possess a high affinity at 5-HT1A receptors and an agonist efficacy, as measured by Emax values from a cellular activation assay, that is higher than that of the compounds described in prior art. The capacity of the compounds of the invention to activate an effector protein complex is higher than that the most efficacious agonist described in prior art. Compounds of the invention also exhibit an exceptionally high selectivity (Ki ratio greater than 1000-fold) with respect, in particular, to dopamine D2 receptors and adrenergic receptors of the alpha1 subtype. This selectivity which constitutes a great advantage since it means that the compounds will avoid inducing (central and peripheral) effects associated with activating or inhibiting such receptors
    本发明所涉及的化合物对 5-HT1A 受体具有高亲和力,并且根据细胞活化实验的 Emax 值衡量,其激动剂功效高于现有技术中所述的化合物。本发明化合物激活效应蛋白复合物的能力高于现有技术中最有效的激动剂。本发明的化合物还具有极高的选择性(Ki 比值大于 1000 倍),特别是对多巴胺 D2 受体和α1 亚型肾上腺素能受体。这种选择性具有很大的优势,因为它意味着本发明化合物可以避免引起与激活或抑制这些受体相关的(中枢和外周)效应。
  • Compounds for treating disorders sensitive to serotoninergic regulation controlled by the 5-HT1A receptors
    申请人:NEUROLIXIS
    公开号:US10562853B2
    公开(公告)日:2020-02-18
    The invention concerns compounds that possess a high affinity at 5-HT1A receptors and an agonist efficacy, as measured by Emax values from a cellular activation assay, that is higher than that of the compounds described in prior art. The capacity of the compounds of the invention to activate an effector protein complex is higher than that the most efficacious agonist described in prior art. Compounds of the invention also exhibit an exceptionally high selectivity (Ki ratio greater than 1000-fold) with respect, in particular, to dopamine D2 receptors and adrenergic receptors of the alpha1 subtype. This selectivity which constitutes a great advantage since it means that the compounds will avoid inducing (central and peripheral) effects associated with activating or inhibiting such receptors.
    本发明所涉及的化合物对 5-HT1A 受体具有高亲和力,并且根据细胞活化实验的 Emax 值衡量,其激动剂功效高于现有技术中所述的化合物。本发明化合物激活效应蛋白复合物的能力高于现有技术中最有效的激动剂。本发明的化合物还具有极高的选择性(Ki 比值大于 1000 倍),特别是对多巴胺 D2 受体和α1 亚型肾上腺素能受体。这种选择性具有很大的优势,因为它意味着本发明的化合物可以避免引起与激活或抑制这些受体相关的(中枢和外周)效应。
  • NEW-4-(PYRROLOPYRIMIDIN-6-YL)BENZENESULPHONAMIDE DERIVATIVES
    申请人:Laboratorios Almirall, S.A.
    公开号:EP1492793B1
    公开(公告)日:2008-01-16
  • US7504398B2
    申请人:——
    公开号:US7504398B2
    公开(公告)日:2009-03-17
查看更多